Risk of serious opportunistic infections after solid organ transplantation: Interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 7, 2014, Pages 881-896

  Kalil, Andre C ^a   Florescu, Marius C ^a   Grant, Wendy ^a   Miles, Clifford ^a   Morris, Michael ^a   Stevens, R Brian ^b   Langnas, Alan N ^a   Florescu, Diana F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

IL 2 receptor antagonists; Induction; Infection; Polyclonal antibodies

Indexed keywords

ANTIVIRUS AGENT; BASILIXIMAB; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; LYMPHOCYTE ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR;

ACUTE GRAFT REJECTION; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG RESPONSE; GRAFT FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ANTAGONISTS AND INHIBITORS; COMPLICATION; GRAFT REJECTION; HISTOCOMPATIBILITY; META ANALYSIS; MICROBIOLOGY; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-2; RISK ASSESSMENT; TRANSPLANTATION IMMUNOLOGY;

EID: 84902471993     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.917046     Document Type: Article

References (107)

1. Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 8:1771-7
2. Meier-Kriesche H.U, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006;6:1111-31
3. Bogetti D, Sankary HN, Jarzembowski TM, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005;19:507-11
4. Wilson C, Brook NR, Gok MA, et al. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial. Transplant Proc 2005;37:1774-5
5. Sellers MT, McGuire BM, Haustein SV, et al. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation 2004;78:1212-17
6. Zhang R, Haverich A, Struber M, et al. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant 2008;27:603-9
7. Wilson CH, Brook NR, Gok MA, et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005;92:681-7
8. Belitsky P, MacDonald AS, Lawen J, et al. Use of rabbit anti-thymocyte globulin for induction immunosuppression in high-risk kidney transplant recipients. Transplant Proc 1997;29:16S-7S
9. Gaston RS, Hudson SL, Deierhoi MH, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992;53:103-9
10. Augustine JJ, Poggio ED, Heeger PS, Hricik DE. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008;86:529-34
11. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003;326:789
12. Grego K, Arnol M, Bren AF, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Transplant Proc 2007;39:3093-7
13. Pham K, Kraft K, Thielke J, et al. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005;37:899-902
14. Vega O, Cardenas G, Correa-Rotter R, et al. Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. Rev Invest Clin 2008;60: 82-6
15. Nair MP, Nampoory MR, Johny KV, et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001;33:2767-9
16. Martins L, Henriques AC, Dias L, et al. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results. Transplant Proc 2000;32:2623-5
17. Nampoory MR, Abdulhalim M, Johny KV, et al. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction. Transplant Proc 2002;34: 2916-19
18. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-77
19. Jindal RM, Das NP, Neff RT, et al. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. Am J Nephrol 2009;29:501-8
20. Al Najjar A, Etienne I, Le Pogamp P, et al. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006;38:2298-9
21. Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005;79:716-21
22. Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004;78:904-10
23. Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009;20: 1385-92
24. Banhegyi C, Rockenschaub S, Muhlbacher F, et al. Preliminary results of a prospective randomized clinical trial comparing cyclosporine A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation. Transplant Proc 1991;23:2207-8
25. Barnhart GR, Goldman MH, Hastillo A, et al. Comparison of immunosuppression therapy following heart transplantation: pretransfusion/ azathioprine/ATG/prednisone versus cyclosporine/prednisone. J Heart Transplant 1985;4:381-4
26. Belitsky P, MacDonald AS, Cohen AD, et al. Comparison of antilymphocyte globulin and continuous i.v. cyclosporine A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study. Transplant Proc 1991;23:999-1000
27. Bell PR, Blamey RW, Briggs JD, et al. Medical research council trial of antilymphocyte globulin in renal transplantation. A multicenter randomized double-blind placebo controlled clinical investigation. Transplantation 1983;35: 539-45
28. Cantarovich D, Karam G, Giral-Classe M, et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998;54:1351-6
29. Charpentier B; European Tacrolimus vs Microemulsified Cyclosporin Study Group. A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. Transplant Proc 2002;34:1625-6
30. Chatterjee SN. Antithymocyte globulin in renal transplant recipients. Report of a prospective randomized controlled trial. Arch Surg 1976;111:680-3
31. Cosimi AB, Wortis HH, Delmonico FL, Russell PS. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery 1976;80:155-63
32. Diethelm AG, Blackstone E, Whelchel JD, et al. The adjunctive value of equine antithymocyte membrane globulin in a randomized study of patients undergoing cadaveric renal transplantation. Transplant Proc 1979;11:27-30
33. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003;75: 1396-9
34. Jakobsen A, Sodal G, Flatmark A, Thorsby E. Antilymphocyte globulin in cadaveric renal transplantation-a controlled trial. Scand J Urol Nephrol Suppl 1977(42):94-6
35. Jonas S, Kling N, Bechstein WO, et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. Clin Transplant 1995;9:406-14
36. Kahn D, Botha JF, Pascoe MD, et al. Withdrawal of cyclosporine in renal transplant recipients with acute tubular necrosis improves renal function. Transpl Int 2000;13(Suppl 1):S82-3
37. Kasiske BL, Johnson HJ, Goerdt PJ, et al. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997;30:639-45
38. Kreis H, Mansouri R, Descamps JM, et al. Antithymocyte globulin in cadaver kidney transplantation: a randomized trial based on T-cell monitoring. Kidney Int 1981;19: 438-44
39. Khosroshahi HT, Tubbs RS, Shoja MM, et al. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. Transplant Proc 2008;40:137-9
40. Koga A, Moreso FJ, Seron D, et al. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome. Transplant Proc 2004;36:1305-7
41. Langrehr JM, Klupp J, Junge G, et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. Transplant Proc 2001;33:2330-1
42. Hesse UJ, Fryd DS, Chatterjee SN, et al. Pulmonary infections. The Minnesota randomized prospective trial of cyclosporine vs azathioprine- antilymphocyte globulin for immunosuppression in renal allograft recipients. Arch Surg 1986;121:1056-60
43. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001;72:1050-5
44. Najarian JS, Fryd DS, Strand M, et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985;201:142-57
45. Neuhaus P, Klupp J, Langrehr MJ, et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. Transplantation 2000;69:2343-53
46. Novick AC, Hwei HH, Steinmuller D, et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 1986;42:154-8
47. Novick AC, Braun WE, Steinmuller D, et al. A controlled randomized double-blind study of antilymphoblast globulin in cadaver renal transplantation. Transplantation 1983;35:175-9
48. Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999;116:127-33
49. Samsel R, Rowinski W, Chmura A, et al. Perioperative administration of single, high-dose of ATG-Fresenius-S as an induction immunosuppressive therapy in cadaveric renal transplantation: preliminary results. Transplant Proc 2001;33:2952-4
50. Samsel R, Pliszczynski J, Chmura A, et al. Safety and efficacy of high dose ATG bolus administration on revascularization in kidney graft patients-long term results. Ann Transplant 2008;13:32-9
51. Sansom JR, Barnes AD, Hall CL. A randomized prospective clinical trial of antilymphocyte globulin in 100 cadaveric renal transplants. Postgrad Med J 1976;52: 75-8
52. Sheashaa HA, Hamdy AF, Bakr MA, et al. Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. Int Urol Nephrol 2008;40: 515-20
53. Slakey DP, Johnson CP, Callaluce RD, et al. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function. Transplantation 1993;56:827-31
54. Sutherland DE, Goetz FC, Najarian JS. One hundred pancreas transplants at a single institution. Ann Surg 1984;200: 414-40
55. Sutherland DE, Fryd DS, Strand MH, et al. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Am J Kidney Dis 1985;5:318-27
56. Taylor HE, Ackman CF, Horowitz I. Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation. Can Med Assoc J 1976;115:1205-8
57. Thibaudin D, Alamartine E, de Filippis JP, et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998;13: 711-15
58. Wadstrom J, Brekke B, Wramner L, et al. Triple versus quadruple induction immunosuppression in pancreas transplantation. Transplant Proc 1995;27: 1317-18
59. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-42
60. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001;72:1261-7
61. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003;75:37-43
62. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005;80:1734-41
63. Tan J, Yang S, Wu W. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients. Transplant Proc 2005;37:903-5
64. Parrott NR, Hammad AQ, Watson CJ, et al. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation 2005;79:344-8
65. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999;67:276-84
66. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005;24:1297-304
67. Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006;6: 1666-72
68. Spada M, Petz W, Betani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006;6:1913-21
69. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999;67:110-15
70. Folkmane I, Bicans J, Amerika D, et al. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab. Transplant Proc 2001;33:3209-10
71. Sheashaa HA, Bakr MA, Ismail AM, et al. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol 2005;25: 221-5
72. Schmeding M, Sauer IM, Kiessling A, et al. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 2007;12:15-21
73. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352:2705-13
74. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005;11:1064-72
75. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-5
76. Lietz K, John R, Beniaminovitz A, et al. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy. Transplantation 2003;75:781-7
77. Boillot O, Mayer DA, Boudjema K, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005;11:61-7
78. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003;75:1260-6
79. Heffron TG, Pillen T, Smallwood GA, et al. Pediatric liver transplantation with daclizumab induction. Transplantation 2003;75:2040-3
80. ter Meulen CG, van Riemsdijkl, Hene RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004;4: 803-10
81. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807-14
82. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006;82:62-8
83. Kato T, Yoshida H, Sadfar K, et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005;37:1217-19
84. Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002;2:568-73
85. Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13:1521-31
86. Ji SM, Li LS, Cheng Z, et al. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience. Transplant Proc 2007;39: 1396-401
87. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007;7:560-70
88. Gelens MA, Christiaans MH, van Heurn EL, et al. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation 2006;82:1221-3
89. Otero A, Varo E, de Urbina JO, et al. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009;15:1542-52
90. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009;9:327-36
91. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669-73
92. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994;57:685-94
93. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995;59:1194-200
94. Raefsky EL, Gascon P, Gratwohl A, et al. Biological and immunological characterization of ATG and ALG. Blood 1986;68:712-19
95. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009;48:772-86
96. Goebel J, Stevens E, Forrest K, Roszman TL. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol 2000;8:153-9
97. Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 1994;369:333-6
98. Nakamura Y, Russell SM, Mess SA, et al. Heterodimerization of the IL-2 receptor beta-and gamma-chain cytoplasmic domains is required for signalling. Nature 1994;369:330-3
99. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993;11:245-68
100. Binder M, Vogtle FN, Michelfelder S, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 2007;67:3518-23
101. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177-88
102. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
103. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
104. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-101
105. Turcotte JG, Feduska NJ, Haines RF, et al. Antithymocyte globulin in renal transplant krecipients. A clinical trial. Arch Surg 1993;106(4):484-88
106. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991;51(1): 107-13
107. Garcia R, Machado PG, Felipe CR, et al. Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients. Braz J Med Biol Res 2007;40(4): 457-65